Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795621 | 0.87 | LMNA (0.39) | ITGB3ITGA2BMEN1KMT2ALTB4R | |
| SCHEMBL7788854 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BMEN1KMT2ALTB4R | |
| SCHEMBL7795117 | 0.81 | ITGB3 (0.44) | ITGB3ITGA2BMEN1KMT2ALTB4R | |
| SCHEMBL7588938 | 0.77 | LMNA (0.38) | ITGB3ITGA2BITGAVPOLB | |
| SCHEMBL7592919 | 0.75 | LMNA (0.37) | ITGB3ITGA2BLTB4R2POLB | |
| SCHEMBL7796051 | 0.74 | MAPK1 (0.43) | LTB4RLTB4R2L3MBTL1POLB | |
| SCHEMBL7499998 | 0.72 | ITGB3 (0.55) | ITGB3ITGA2BMEN1KMT2ALTB4R | |
| SCHEMBL7796040 | 0.72 | ITGB3 (0.40) | ITGB3ITGA2BITGAVPOLB | |
| SCHEMBL8381416 | 0.71 | ITGB3 (1.00) | ITGB3ITGA2BMEN1KMT2ALTB4R | |
| SCHEMBL7798164 | 0.71 | ITGB3 (0.61) | ITGB3ITGA2BMEN1KMT2ALTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | claimed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | ITGB3 132/4885ITGA2B 106/4885MEN1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.